Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Andrx Corporation (NasdaqNM:ADRX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
4955 Orange Drive
Davie, FL 33314
Phone: (954) 584-0300
Fax: (954) 792-1034
Email: amalahias@andrx.com
Employees (last reported count): 970
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 27%
·Over the last 6 months:
 · 8 insider sells; 1.47M shares
  (7.2% of insider shares)
·Institutional: 60% (82% of float)
(387 institutions)
·Net Inst. Buying: 4.71M shares (+10.09%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using its proprietary drug delivery technologies. Andrx markets and sells Cartia XT and Diltia XT, its generic or bioequivalent versions of Cardizem CD and Dilacor XR. Andrx uses its proprietary drug delivery technologies and formulation skills to develop bioequivalent versions of selected controlled-release brand name pharmaceuticals; and brand name controlled-release formulations of existing immediate-release or controlled-release drugs. Andrx is also developing bioequivalent versions of specialty or niche pharmaceutical products. Through its distribution operations, Andrx primarily sells bioequivalent drugs manufactured by third parties primarily to independent pharmacies, pharmacy chains which do not maintain their own central warehousing facilities, pharmacy buying groups and physicians' offices.
More from Market Guide: Expanded Business Description

Financial Summary
Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using the Company's proprietary drug delivery technologies. For the six months ended 6/30/01, revenues totaled $338.2 million. Net income applicable to Andrx Group totaled $43.4 million. Results are not comparable due to the 9/00 reorganization of the company's common stock into two new classes of tracking stocks. The two classes are Andrx Common Stock and Cybear Common Stock.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Alan Cohen, 46
Co-Chairman, CEO
$515K--  
Chih-Ming Chen, Ph. D., 49
Co-Chairman
513K--  
Elliot Hahn, Ph.D., 56
Pres
2.3M$1.9M
Scott Lodin, 45
Exec. VP, Gen. Counsel, Pres of Andrx Pharmaceuticals
4.8M4.4M
Angelo Malahias, 39
VP, CFO
2.6M2.4M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ADRXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 15-Mar-2001
$38.50 
Recent Price$70.29 
52-Week High
on 8-Sep-2000
$95.875
Daily Volume (3-month avg)1.14M
Daily Volume (10-day avg)1.12M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
26-Week Change+17.8%
26-Week Change
relative to S&P500
+28.2%
Share-Related Items
Market Capitalization$4.93B
Shares Outstanding70.1M
Float51.2M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 4-Apr-2000
Per-Share Data
Book Value (mrq)$8.95 
Earnings (ttm)$0.95 
Earnings (mrq)$0.34 
Sales (ttm)$8.44 
Cash (mrq)$4.01 
Valuation Ratios
Price/Book (mrq)7.86 
Price/Earnings (ttm)74.07 
Price/Sales (ttm)8.33 
Income Statements
Sales (ttm)$615.6M
EBITDA (ttm)$78.0M
Income available to common (ttm)$68.6M
Profitability
Profit Margin (ttm)7.7%
Operating Margin (ttm)10.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)7.15%
Return on Equity (ttm)12.29%
Financial Strength
Current Ratio (mrq)4.89 
Debt/Equity (mrq)0 
Total Cash (mrq)$280.9M
Short Interest
As of 8-Aug-2001
Shares Short1.51M
Percent of Float2.9%
Shares Short
(Prior Month)
1.76M
Short Ratio1.01 
Daily Volume1.49M
See Profile Help for a description of each item above;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.